EULAR Management of Rheumatoid Arthritis with Disease-Modifying Antirheumatic Drugs

from Clinical Guideline InSights · host Guideline Central

The 2026 EULAR guideline on Management of Rheumatoid Arthritis with Synthetic and Biologic Disease-Modifying Antirheumatic Drugs, summarizing key recommendations on DMARD therapy, treatment targets, and more.Management of Rheumatoid Arthritis with Synthetic and Biologic Disease-Modifying Antirheumatic DrugsEuropean League Against Rheumatism (EULAR)March 13 2026Guideline Summary: https://www.guidelinecentral.com/guideline/5135295Full-Text: https://ard.eular.org/article/S0003-4967(26)00075-0/fulltext

Episode metadata supplied by the publisher feed · Published Apr 2, 2026

Embed this episode

Attribution link and audio player

NOW PLAYING

EULAR Management of Rheumatoid Arthritis with Disease-Modifying Antirheumatic Drugs

0:00 2:44

1×

No transcript for this episode yet

We transcribe on demand. Request one and we'll notify you when it's ready — usually under 10 minutes.

Share this episode

Similar Episodes

No similar episodes found.

Similar Podcasts

No similar podcasts found.

Frequently Asked Questions

How long is this episode of Clinical Guideline InSights?

This episode is 2 minutes long.

When was this Clinical Guideline InSights episode published?

This episode was published on April 2, 2026.

Can I download this Clinical Guideline InSights episode?

Yes. Use the download control on the episode player to save the publisher-provided media file.

URL copied to clipboard!